Key features and details
- Mouse monoclonal [TVG 701Y] to Human Papillomavirus 16 (E7)
- Suitable for: WB, ELISA, Flow Cyt, IHC-Fr
- Isotype: IgG2a
Product nameAnti-Human Papillomavirus 16 (E7) antibody [TVG 701Y]
DescriptionMouse monoclonal [TVG 701Y] to Human Papillomavirus 16 (E7)
Tested applicationsSuitable for: WB, ELISA, Flow Cyt, IHC-Frmore details
Species reactivityReacts with: Other species
Full length protein (HPV 16 E7) synthesised from S. pombe.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferConstituent: PBS
Concentration information loading...
PurityProtein A/G purified
Clone numberTVG 701Y
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab20191 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent concentration. Can be blocked with Recombinant Human papillomavirus Human Papillomavirus 16 (E7) protein (His tag) (ab237790).|
|ELISA||Use at an assay dependent concentration.|
|Flow Cyt||Use at an assay dependent concentration.
ab170191 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
|IHC-Fr||Use at an assay dependent concentration.|
RelevanceE7 protein has both transforming and trans-activating activities. Disrupts the function of host retinoblastoma protein RB1/pRb, which is a key regulator of the cell cycle. Induces the disassembly of the E2F1 transcription factors from RB1, with subsequent transcriptional activation of E2F1-regulated S-phase genes. Inactivation of the ability of RB1 to arrest the cell cycle is critical for cellular transformation, uncontrolled cellular growth and proliferation induced by viral infection. Stimulation of progression from G1 to S phase allows the virus to efficiently use the cellular DNA replicating machinery to achieve viral genome replication. Interferes with histone deacetylation mediated by HDAC1 and HDAC2, leading to activation of transcription
- E7 antibody
- HPV16 E7 antibody
- Protein E7 antibody
- Transforming protein antibody
ab20191 has been referenced in 5 publications.
- Chen Y et al. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system. Antiviral Res 178:104794 (2020). PubMed: 32298665
- Yang J et al. Notch signaling is important for epithelial-mesenchymal transition induced by low concentrations of doxorubicin in osteosarcoma cell lines. Oncol Lett 13:2260-2268 (2017). PubMed: 28454389
- Kannan A et al. Genetic Mutation and Exosome Signature of Human Papilloma Virus Associated Oropharyngeal Cancer. Sci Rep 7:46102 (2017). PubMed: 28383029
- Harris M et al. Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein. Br J Cancer 108:859-65 (2013). PubMed: 23385729
- Tommasino M et al. HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene 8:195-202 (1993). PubMed: 8380917